AstraZeneca PLC Buys Into Regulus Therapeutics, Inc.' MicroRNA Therapeutics for $28 Million

Published: Aug 15, 2012

Regulus Therapeutics has formed a strategic alliance with AstraZeneca to discover, develop, and commercialize microRNA therapeutics for cardiovascular and metabolic diseases and oncology. The collaboration will focus on three microRNA targets, which include Regulus' lead cardiovascular/metabolic disease program targeting microRNA-33 for the treatment of atherosclerosis. According to the agreement, AstraZeneca will make a $28m payment which includes an equity investment and an upfront payment to Regulus.

Back to news